Search | Clinical Trials Finder

Conditions: Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Macular Degeneration
Interventions: IMT - Implantable Miniature Telescope; Device
Lead sponsor: VisionCare, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 28
States / cities: Tucson, Arizona • Irvine, California • Los Altos, California + 24 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Medication Adherence, Glaucoma
Interventions: eyeGuide; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Blindness
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Ocular Physiology
Interventions: Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock, Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Migraine Disorders, Photophobia
Interventions: Therapeutic Lens Coating, Sham Lens Coating; Other
Lead sponsor: Bradley Katz; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: OTX-TKI (axitinib implant), Aflibercept; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 97
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more

Conditions: Myopia, Hyperopia, Cataract
Interventions: IOLMASTER 700 TK; Device
Lead sponsor: Advanced Vision Care; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Bakersfield, California • Los Angeles, California • Torrance, California + 4 more

Conditions: Cataract, Refractive Error, Low Vision
Interventions: Visual impairment intervention program; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 2,544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Trachoma
Interventions: water and health education program to improve hygiene; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Months to 65 Months
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more

Conditions: Allergic Conjunctivitis
Interventions: CsA high dose, CsA low dose, PA, Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Blindness
Interventions: BrainPort; Device
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 10 Years to 24 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2
Interventions: RNA antisense oligonucleotide for intravitreal injection; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more

Conditions: Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining
Interventions: CLM2 topical gel, Placebo topical gel; Drug
Lead sponsor: Glia, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Presbyopia
Interventions: Clerio Vision LIRIC-modified Bifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, Clerio Vision Single Vision Contact Lens; Device
Lead sponsor: Clerio Vision, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma, Open-Angle
Interventions: H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 56
States / cities: Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 42 more

Conditions: Refractive Error Correction, Visual Acuity
Interventions: Metric-optimized spectacles, Routine Clinical Spectacles; Device
Lead sponsor: Ohio State University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Inflammatory Reaction Due to Ocular Lens Prosthesis
Interventions: IBI-10090; Drug
Lead sponsor: ICON Bioscience Inc; Industry
Eligibility: 40 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions: Visual Performance tests, Brain-computer interface; Diagnostic Test · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions: Tolvaptan Suspension, Tolvaptan Tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 28 Days to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more

Search by objective public record fields.

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

A Long-Term Monitoring Study of the IMT-002 Patients

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program

Determine the Effect of Intraocular Pressure (IOP), Optic Nerve Imaging, Venous Congestion in Volunteers Prone Position 5 Hours

Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Accuracy of IOLMASTER 700 Total Keratometry (TK)

A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents

Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

Bifocal Contact Lens Study for Adults With Age-Related Near Vision Loss

H-1337 Ophthalmic Solution Phase 1/2

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)